Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.46 |
| ▸ | CHRNG | P07510 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.46 |
| ▸ | CHRND | Q07001 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359134 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL6359132 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL23213832 | 0.76 | PDK2 (0.41) | SLC6A3SLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL29844871 | 0.76 | PDK2 (0.41) | SLC6A3SLC6A4ALDH1A1MEN1KMT2A | |
| SCHEMBL6359173 | 0.70 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7057462 | 0.69 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL23467635 | 0.68 | JAK2 (0.37) | — | |
| SCHEMBL7667956 | 0.68 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL28931043 | 0.67 | ALDH1A1 (0.34) | SLC6A3ALDH1A1 | |
| SCHEMBL28931041 | 0.67 | SLC6A3 (0.46) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885SLC6A3 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.